Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Ellis

Showing results (871-880 of 1,150) with videos related to

Pageof 115
Sort By:
American Heart Journal|June 3, 2008
Safety and efficacy of overlapping sirolimus-eluting versus paclitaxel-eluting stentsMehdi H Shishehbor, Reza Amini, Russell E Raymond, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|September 17, 2009
Integrated analysis of medically treated diabetic patients in the TAXUS(R) program: benefits across stent platforms, paclitaxel release formulations, and diabetic treatmentsKeith D Dawkins, Gregg W Stone, Antonio Colombo, et al.
Journal of the American College of Cardiology|March 1, 1992
Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study GroupT C Wall, R M Califf, B S George, et al.
Journal of the American Heart Association|October 31, 2018
Long-Term Time-Varying Risk of Readmission After Acute Myocardial InfarctionUmesh N Khot, Michael J Johnson, Newton B Wiggins, et al.
Regulatory Toxicology and Pharmacology : RTP|June 15, 2015
Use of an aggregate exposure model to estimate consumer exposure to fragrance ingredients in personal care and cosmetic productsB Safford, A M Api, C Barratt, et al.
Coronary Artery Disease|February 1, 1993
Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplastyS G Ellis, J E Tcheng, F I Navetta, et al.
Lancet (London, England)|April 9, 1994
Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC InvestigatorsE J Topol, R M Califf, H F Weisman, et al.
Circulation|January 1, 1991
Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter studyR A Schatz, D S Baim, M Leon, et al.
American Heart Journal|December 13, 2005
Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV TrialAmir Halkin, Roxana Mehran, Christopher W Casey, et al.
The Journal of Invasive Cardiology|May 7, 2013
Outcomes of culprit versus multivessel PCI in patients with multivessel coronary artery disease presenting with ST-elevation myocardial infarction complicated by shockMatthew A Cavender, Jeevanantham Rajeswaran, Linda DiPaola, et al.
Pageof 115

Showing results (871-880 of 1,150) with videos related to

Sort By:
Pageof 115
American Heart Journal|June 3, 2008
Safety and efficacy of overlapping sirolimus-eluting versus paclitaxel-eluting stentsMehdi H Shishehbor, Reza Amini, Russell E Raymond, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|September 17, 2009
Integrated analysis of medically treated diabetic patients in the TAXUS(R) program: benefits across stent platforms, paclitaxel release formulations, and diabetic treatmentsKeith D Dawkins, Gregg W Stone, Antonio Colombo, et al.
Journal of the American College of Cardiology|March 1, 1992
Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study GroupT C Wall, R M Califf, B S George, et al.
Journal of the American Heart Association|October 31, 2018
Long-Term Time-Varying Risk of Readmission After Acute Myocardial InfarctionUmesh N Khot, Michael J Johnson, Newton B Wiggins, et al.
Regulatory Toxicology and Pharmacology : RTP|June 15, 2015
Use of an aggregate exposure model to estimate consumer exposure to fragrance ingredients in personal care and cosmetic productsB Safford, A M Api, C Barratt, et al.
Coronary Artery Disease|February 1, 1993
Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplastyS G Ellis, J E Tcheng, F I Navetta, et al.
Lancet (London, England)|April 9, 1994
Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC InvestigatorsE J Topol, R M Califf, H F Weisman, et al.
Circulation|January 1, 1991
Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter studyR A Schatz, D S Baim, M Leon, et al.
American Heart Journal|December 13, 2005
Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV TrialAmir Halkin, Roxana Mehran, Christopher W Casey, et al.
The Journal of Invasive Cardiology|May 7, 2013
Outcomes of culprit versus multivessel PCI in patients with multivessel coronary artery disease presenting with ST-elevation myocardial infarction complicated by shockMatthew A Cavender, Jeevanantham Rajeswaran, Linda DiPaola, et al.
Pageof 115